CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab

Here, we report on a novel bispecific antibody-derivative, designated RTX-CD47, with unique capacity for CD20-directed inhibition of CD47-SIRPα “don't eat me” signaling. RTX-CD47 comprises a CD20-targeting scFv antibody fragment derived from rituximab fused in tandem to a CD47-blocking scFv. Si...

Descripción completa

Detalles Bibliográficos
Autores principales: van Bommel, Peter E., He, Yuan, Schepel, Ilona, Hendriks, Mark A. J. M., Wiersma, Valerie R., van Ginkel, Robert J., van Meerten, Tom, Ammatuna, Emanuele, Huls, Gerwin, Samplonius, Douwe F., Helfrich, Wijnand, Bremer, Edwin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749665/
https://www.ncbi.nlm.nih.gov/pubmed/29308308
http://dx.doi.org/10.1080/2162402X.2017.1386361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749665/
https://www.ncbi.nlm.nih.gov/pubmed/29308308
http://dx.doi.org/10.1080/2162402X.2017.1386361

Ejemplares similares